Health Behavior Intervention for Colorectal Cancer Patients
Condition(s) studied
Investigational drug(s) / intervention(s)
health behavior intervention programs based on the temporal self-regulation theory are also received: The intervention group received additional health behavior intervention programs based on the temporal self-regulation theory in addition to the routine post-operative health education services provided by the hospital. The intervention period was set as 1 session per week for a total of 6 weeks, each session lasting approximately 45-60 minutes. The intervention was conducted in a combination of offline and online guidance and support. Before the intervention, baseline assessments were conducted for the research subjects, and intervention manuals, demonstration videos, and other tools were distributed. From the 1st to the 5th week, corresponding module measures were implemented according to the intervention framework, including looking to the future, intention strengthening, habit shaping, and self-control. In the 6th week, progress summaries, feedback, and long-term plan formulation were carried out. Throughout the process, online WeChat/QQ support groups/Tencent Meeting were u
Study summary
Develop a health behavior intervention plan based on patients' needs and preferences, and preliminarily apply and evaluate the feasibility and effectiveness of this intervention plan for patients with colorectal cancer.
Eligibility
Primary outcome measure(s)
- health behavior — From before the intervention (T0) to 3 months after the intervention (T2)
Measured through the Health Behavior Scale for Cancer Patient
Trial sites (1)
| Facility | City | Region | Status |
|---|---|---|---|
| 101 Longmian Avenue, Jiangning District | Nanjing | Jiangsu |
More Nanjing Medical University trials in China
Other trials for the same condition
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
View NCT07632313 on ClinicalTrials.gov ↗ ← All trials in China